Intra-Cellular Therapies EBIT

As of the most recent data (December 2024), ITCI shows a EBIT of $-120M. That compares with $-160M in the prior-year period — up 26.9% year over year. That is below the Healthcare sector average of $99B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ITCI's EBIT is now $-120M (was $-160M) — a 26.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Intra-Cellular Therapies is outperforming or lagging.

The Healthcare sector average EBIT is about $99B. Intra-Cellular Therapies is at $-120M, which is lower that average. That is roughly 100.1% below the sector mean. Use the comparison chart on this page to see how ITCI stacks up against individual peers as well.

Tracking ITCI's ebit over time shows whether Intra-Cellular Therapies is scaling, shrinking, or reshaping that part of the business. The current reading is $-120M That compares with $-160M in the prior-year period — up 26.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Intra-Cellular Therapies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-120M) with ownership activity and broader fundamentals.